One consequence of the recent interest in psychotomimetic drugs has been a search for pharmacological agents that will "block" drug-induced psychological disturbances and hallucinations. Fabing1reported that azacyclonol (Frenquel) in small doses prevented the occurrence of lysergic acid diethylamide (LSD-25) "psychoses" in man, although one of us (L. D. C.) was unable to verify this...
Feldberg and Sherwood's* previous studies of the behavior of cats after the intraventricular injection of various drugs opened up a new method of investigation. By this technique they showed that drugs injected into this area of high pharmacologic sensitivity could evoke various complex behavioral responses and conditions resembling sleep, anesthesia, profound muscular weakness, catatonia, and...
This is an account of a model psychosis (6) produced by eating the seed of a tropical American plant which is known in Mexico as ololiuqui. It is only quite recently that Schultes (16) has made order from chaos in the matter of the identity of a climbing vine calledRivea corymbosa.I was introduced to ololiuqui by Mr. Leslie LeCron during a visit to Los Angeles in which he showed me Taylor's...
This paper presents an example of the depersonalization syndrome as experienced and described by an intelligent patient. Considering the frequency of its occurrence, this syndrome has not been as often recognized nor as adequately described as would be expected. The syndrome was first described by Mayer-Gross (1935), later by Gordon (1936), Shorvon (1946, 1947) and Tayleur Stockings (1947). The...
Psychoactive drugs profoundly alter consciousness, but the neural mechanisms by which they do so remain poorly understood. Global workspace theory may provide a framework for investigating these mechanisms. The global workspace, a candidate neural substrate of consciousness, is a set of brain regions that integrate and disseminate information to the rest of the brain. According to a recent...
The term “psychedelic” lacks a consensus definition, yet a growing body of regulatory and commercial infrastructure—FDA clinical-trial guidance, AMA reimbursement codes, research grants, and insurance coverage decisions—turns on whether a given substance falls within the category. This short essay argues that the boundaries of the “psychedelic” label are doing significant normative work that is...